AG真人官方

On July 1, 2025, Pegasystems Inc. (NASDAQ: PEGA) Chief Operating Officer and Chief Financial Officer Kenneth Stillwell reported the sale of 4,000 common shares on SEC Form 4.

• 3,000 shares sold at a weighted-average price of $52.31 (range $51.88-$52.67).
• 1,000 shares sold at a weighted-average price of $53.64 (range $53.05-$53.94).

The transactions were executed under a Rule 10b5-1 pre-arranged trading plan adopted on August 29, 2024, limiting discretionary timing and reducing potential insider-trading concerns.

Following the sales鈥攁nd after accounting for the 2-for-1 stock split effective June 20, 2025 and purchases through the employee stock purchase plan鈥擲tillwell directly owns 49,350 shares. No derivative securities were acquired or disposed of, and no additional insider transactions were disclosed in this filing.

Forager Capital Management, LLC, together with its affiliated investment vehicle Forager Fund, L.P. and principals Edward Kissel and Robert MacArthur, has filed a Schedule 13G disclosing ownership of 2,186,472 shares of Viemed Healthcare, Inc. (VMD) common stock.

The position represents 5.5 % of Viemed鈥檚 39.52 million shares outstanding as reported in the company鈥檚 10-Q for the quarter ended 31 Mar 2025. Because the stake exceeds the 5 % threshold, the group is required to disclose its holdings under Section 13(d) of the Exchange Act. The filing is made pursuant to Rule 13d-1(b), indicating that the investors view the holding as passive rather than activist.

Voting and dispositive powers are split as follows: (i) Forager Fund and Forager Capital Management each hold sole voting and dispositive power over the full 2.19 million shares; (ii) Messrs. Kissel and MacArthur share voting and dispositive power over the same shares through their control of the fund and general partner. No other party is reported to have an economic interest in the shares.

The event date is 24 Jun 2025, with the joint filing signed on 1 Jul 2025. The certification clause confirms that the securities were not acquired with the intent to change or influence control of the issuer.

• The disclosure introduces a new institutional shareholder representing a sizeable block for a small-cap healthcare company.
• Filing type (Schedule 13G vs. 13D) suggests a passive, long-only orientation, reducing immediate governance or strategic pressure on Viemed.

Greif, Inc. (GEF) filed a Form 144 disclosing that an insider plans to sell up to 19,248 Class A shares through Fidelity Brokerage Services on or about 01 July 2025. The block carries an aggregate market value of $1.35 million and represents approximately 0.07 % of the 26.13 million Class A shares outstanding.

The filing also lists a prior disposition: on 09 June 2025 the same individual, named as Ole Rosgaard, sold 30,000 Class A shares for gross proceeds of $1.97 million. Taken together, recent and proposed sales total 49,248 shares, or roughly 0.19 % of the current float.

The shares to be sold were acquired on 16 January 2024 via restricted-stock vesting and are being sold for the insider鈥檚 own account. No operational, earnings or strategic information is included; the document strictly serves as notice under Rule 144 and contains the standard representation that the seller is not in possession of undisclosed material adverse information.

For investors, the key takeaway is the continued insider selling activity, which, while small relative to total shares outstanding, may be monitored as a gauge of insider sentiment toward Greif鈥檚 equity.

Nuburu (NYSE: BURU) filed an 8-K (Item 4.02) stating its unaudited Q1 2025 financial statements should no longer be relied upon. Management and the Audit Committee found material, non-cash misstatements stemming from incorrect fair-value assumptions for certain convertible notes and failure to re-measure them upon conversion. The errors understated additional paid-in capital and non-operating expense.

The company will file an amended Form 10-Q to restate the affected period under ASC 250. The misstatements relate to a previously disclosed material weakness in internal control over financial reporting. The Audit Committee has discussed the restatement with the independent auditors. Investors should monitor the upcoming restated filing and remediation plans.

Nuburu (NYSE: BURU) has entered into significant convertible note transactions with Bomore Opportunity Group on June 18, 2025. The company executed two key transactions:

• Issued a $1,050,000 convertible note in exchange for 100,000 shares of Series A Preferred Stock
• Issued a $250,000 convertible note in exchange for new capital investment

Both notes are unsecured, non-interest bearing (if not in default), and mature on June 17, 2026. The conversion price is set at the lowest VWAP during the 5 days prior to conversion. Key restrictions include:

• Common stock issuance on conversion limited to 19.9% of outstanding shares until stockholder approval
• Bomore's ownership capped at 9.9% of outstanding common stock
• Notes are subordinate to Series A Preferred Stock regarding dividends and liquidation rights

Nuburu, Inc. (NYSE American: BURU) filed a Form 8-K to update investors on the balance-sheet treatment and ongoing management of its Series A Preferred Stock.

Key disclosure: Starting in Q1 2025, the preferred shares are classified as a current liability because of mandatory redemption provisions. This reclassification shifts the obligation from long-term to short-term debt and could adversely affect liquidity ratios and covenant calculations.

The company has already repurchased and extinguished 100,000 preferred shares. Management is in negotiations to buy back up to an additional 140,000 shares, but there is no assurance the transaction will close. Nuburu also states it 鈥渕ay鈥� pursue further redemptions in the future, leaving open-ended capital-allocation flexibility.

No cash figures, pricing terms, or impact on outstanding share count were provided, and the 8-K was furnished under Item 7.01 (Reg FD), indicating the information is voluntary and not deemed a material definitive agreement.